West Nile virus serology indeterminate on repeat testing — what to do now
Strong recommendation: If clinical suspicion for West Nile neuroinvasive disease remains, repeat serum and CSF WNV IgM with paired acute/convalescent sera (2–3 weeks apart) to document seroconversion or ≥4-fold rise, and prioritize CSF IgM over CSF PCR unless the patient is significantly immunocompromised. 1
- Why this is the safest choice for morbidity, mortality, and quality of life:
- Missed neuroinvasive WNV carries ~10% in-hospital mortality (higher in elderly/immunocompromised) and substantial long-term disability; accurate diagnosis guides prognosis, avoids futile antimicrobials, and focuses supportive neurocritical care and rehab early 2.
- Guideline consensus (encephalitis workup): arboviral CSF PCR is relatively insensitive; CSF/serum IgM improves yield; seropositivity accumulates ~10% per day in week 1; repeat testing and paired sera are recommended when initial tests are negative/indeterminate 1. CSF IgM outperforms CSF PCR for WNV; reserve RT‑PCR mainly for those unable to mount humoral responses 1, 2.
Stepwise algorithm
- Reassess timing and host factors
- If ≤7–10 days from symptom onset: repeat in 7–10 days; IgM may be absent early 1.
- If immunocompromised (e.g., B‑cell depletion, SOT, hematologic malignancy): add CSF and serum WNV RT‑PCR now alongside IgM; IgM may be falsely indeterminate/negative; PCR can be more sensitive here 2.
- Order the right tests now (do all applicable)
- CSF: WNV IgM by EIA/MIA. Avoid relying on CSF PCR in immunocompetent patients due to low sensitivity 1.
- Serum: WNV IgM now AND again at 2–3 weeks to demonstrate seroconversion or ≥4-fold rise (paired sera) if still indeterminate 1.
- If potential cross-reacting flavivirus exposure (travel, vaccination for yellow fever/Japanese encephalitis, dengue/Zika risk): send confirmatory plaque reduction neutralization test (PRNT) on paired sera through public health lab to avoid misclassification that can alter prognosis and counseling 2.
- Interpret indeterminate/discordant results correctly
- Persistently indeterminate or low-positive IgM without rise: consider false positive/cross-reaction; use PRNT to resolve 2.
- Remember: IgM can persist for months to >1 year; a single positive does not prove current infection—hence the emphasis on seroconversion/rising titer and CSF IgM during acute neurologic disease 1, 3.
- If CSF IgM positive with compatible syndrome and seasonality, that supports acute neuroinvasive WNV even if serum is equivocal 1.
- Parallel management to reduce morbidity/mortality now
- Supportive neuro care only; no proven antivirals or immunotherapies improve outcomes; escalate to ICU if encephalitis with airway compromise, seizures, or autonomic instability 2.
- Early rehab and prevention of complications (DVT prophylaxis, aspiration precautions, pressure injury prevention) to protect QOL 2, 4.
- Stop unnecessary antibacterials/acyclovir when alternative diagnoses excluded and WNV confirmed to avoid harm.
- Broaden differential when tests stay indeterminate but suspicion is low or clinical course atypical
- Send alternative encephalitis panel per guideline: HSV/VZV PCR, enterovirus PCR (CSF and throat/stool), EBV serology + CSF PCR, autoimmune encephalitis antibodies (CSF prioritized), especially if course or imaging suggests non-arboviral etiologies 1.
- Pitfall to avoid: overreliance on early negative arboviral tests; repeat because sensitivity rises over days 1.
Practical orders and timing
- Today:
- In 2–3 weeks:
Common pitfalls and how to avoid them
- Pitfall: Using CSF PCR alone in immunocompetent patients → low sensitivity and missed diagnosis. Use CSF IgM first-line 1.
- Pitfall: Treating a single positive serum IgM as “acute” → IgM can persist >1 year; require seroconversion/rising titer or CSF IgM to link to current illness 3, 1.
- Pitfall: Not repeating tests when early or indeterminate → seropositivity rises ~10% per day in week 1; repeat to improve yield 1.
- Pitfall: Ignoring immunosuppression → prioritize RT‑PCR when humoral response is blunted 2.
Short evidence notes:
- Highest‑priority guidance (International Encephalitis Consortium): arboviral diagnosis favors serum/CSF IgM; CSF PCR is insensitive; repeat testing and paired sera to confirm acute infection 1.
- Recent, high‑quality review (JAMA 2025): IgM first-line; confirm with neutralization when cross-reactivity possible; RT‑PCR more useful in severe immunosuppression; no disease‑modifying therapy—supportive care determines outcomes 2.